BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KCNQ2 Cure Alliance - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.kcnq2cure.org
X-WR-CALDESC:Events for KCNQ2 Cure Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20180311T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20181104T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20190310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20191103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20200308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20201101T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20190905T100000
DTEND;TZID=America/Denver:20190905T110000
DTSTAMP:20260405T065039
CREATED:20190726T182847Z
LAST-MODIFIED:20190905T212319Z
UID:76880-1567677600-1567681200@www.kcnq2cure.org
SUMMARY:Update on KCNQ2 Studies in the Channelopathy-associated Epilepsy Research Center without Walls
DESCRIPTION:This webinar will provide updates to the KCNQ2 community regarding ongoing studies by the Channelopathy-associated Epilepsy Research Center without Walls. The main focus will be on efforts to determine the functional consequences of 80 KCNQ2 variants of unknown significance\, and on investigations using human induced pluripotent stem cells (hiPSC) to create KCNQ2-mutant neurons for physiological and pharmacological testing. This work is designed to elucidate molecular and cellular defects associated with KCNQ2 variants and explore pharmacological strategies to correct these defects. \nPresenter:	Alfred L. George\, Jr.\, M.D. (Northwestern University)\nCo-presenter:	Anne Berg\, Ph.D. (Northwestern University)
URL:https://www.kcnq2cure.org/event/update-on-kcnq2-studies-in-the-channelopathy-associated-epilepsy-research-center-without-walls/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20190724T100000
DTEND;TZID=America/Denver:20190724T110000
DTSTAMP:20260405T065039
CREATED:20190723T015641Z
LAST-MODIFIED:20190723T015641Z
UID:76877-1563962400-1563966000@www.kcnq2cure.org
SUMMARY:A New Clinical Trial in KCNQ2-DEE and Upcoming Related Patient Survey
DESCRIPTION:A New Clinical Trial in KCNQ2-DEE and Upcoming Related Patient Survey \nThe KCNQ2 Cure Alliance has invited Dr. John Millichap\, a Pediatric Epileptologist focused on KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)\, and Dr. Simon Pimstone\, CEO of Xenon Pharmaceuticals\, to participate in this webinar. \nModerated by Caroline Loewy from the KCNQ2 Cure Alliance\, topics will include:\n•	How mutations in the KCNQ2 gene for potassium channels in the brain are responsible for KCNQ2-DEE\n•	What we’ve learned to date from off-label use of Potiga®/Trobalt® as a treatment of pediatric KCNQ2-DEE\n•	Challenges of pediatric clinical trials in rare\, genetic epilepsies\n•	Update on XEN496\, a new pediatric formulation Potiga®/Trobalt® currently in development for KCNQ2-DEE\n•	Upcoming patient surveys and how this information will help shape future clinical trials\n•	Panel discussion\, next steps\, and ways to stay informed! \n————————————————————————-\nDr. Millichap is a Pediatric Epileptologist in the Comprehensive Epilepsy Center\, Ann & Robert H. Lurie Children’s Hospital of Chicago\, and Associate Professor of Pediatrics and Neurology at Northwestern University Feinberg School of Medicine. \nDr. Simon Pimstone is the CEO of Xenon Pharmaceuticals\, a company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders\, including rare central nervous system (CNS) conditions\, with a particular focus on epilepsy.
URL:https://www.kcnq2cure.org/event/a-new-clinical-trial-in-kcnq2-dee-and-upcoming-related-patient-survey/
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR